학술논문
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
Document Type
article
Author
Johannes Brägelmann; Carina Lorenz; Sven Borchmann; Kazuya Nishii; Julia Wegner; Lydia Meder; Jenny Ostendorp; David F. Ast; Alena Heimsoeth; Takamasa Nakasuka; Atsuko Hirabae; Sachi Okawa; Marcel A. Dammert; Dennis Plenker; Sebastian Klein; Philipp Lohneis; Jianing Gu; Laura K. Godfrey; Jan Forster; Marija Trajkovic-Arsic; Thomas Zillinger; Mareike Haarmann; Alexander Quaas; Stefanie Lennartz; Marcel Schmiel; Joshua D’Rozario; Emily S. Thomas; Henry Li; Clemens A. Schmitt; Julie George; Roman K. Thomas; Silvia von Karstedt; Gunther Hartmann; Reinhard Büttner; Roland T. Ullrich; Jens T. Siveke; Kadoaki Ohashi; Martin Schlee; Martin L. Sos
Source
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Kinase inhibitors are widely used to treat cancer, however patients frequently develop resistance. Here, the authors investigate adaption mechanisms during drug persistence and show that stimulation of the innate immunity sensor RIG-I enhances cancer cell death when combined with kinase inhibition.